PROCEPT BioRobotics (NASDAQ:PRCT) Announces Quarterly Earnings Results

PROCEPT BioRobotics (NASDAQ:PRCT) released its quarterly earnings data on Wednesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.07), FiscalAI reports. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The business had revenue of $98.29 million during the quarter, compared to the consensus estimate of $100.52 million.

Here are the key takeaways from PROCEPT BioRobotics’ conference call:

• PROCEPT reported third-quarter revenue of $98.3 million, up 18% year over year, with U.S. procedures rising 22% and U.S. handpiece and consumable revenue increasing 21%. Handpiece pricing remained strong, and the company said field inventory had normalized.
• Procedure growth remains challenged by weaker utilization on legacy AquaBeam systems as surgeons shift cases to HYDROS; HYDROS accounts performed more than 35% more procedures than legacy accounts. Management expects about 54,000 procedures for 2026, within its guidance range, but reaching that level implies the strongest sequential procedure growth of the year in Q4.
• The company placed 62 HYDROS systems, including 20 replacements, at an average U.S. selling price of about $495,000. Although greenfield placements fell short of expectations in Q3 due largely to timing, management maintained that it expects to meet or exceed its initial full-year system targets and said capital demand remains healthy.
• The net loss widened to $26.5 million from $21.4 million a year earlier, and adjusted EBITDA loss increased to $9.8 million from $7.4 million as operating expenses rose with investment. Management expects positive adjusted EBITDA in Q4 and described approximately 20% revenue growth in 2027 as a planning baseline, while noting that formal guidance will come later.

PROCEPT BioRobotics Stock Performance

PROCEPT BioRobotics stock traded up $1.49 during trading hours on Wednesday, hitting $21.66. The company had a trading volume of 2,828,443 shares, compared to its average volume of 1,502,198. The firm has a market cap of $1.24 billion, a PE ratio of -11.16 and a beta of 0.88. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. PROCEPT BioRobotics has a one year low of $16.67 and a one year high of $38.11. The firm has a 50-day moving average of $19.33 and a 200 day moving average of $23.27.

Insider Transactions at PROCEPT BioRobotics

In other news, CEO Larry Wood acquired 23,900 shares of PROCEPT BioRobotics stock in a transaction dated Friday, August 7th. The stock was bought at an average price of $20.85 per share, for a total transaction of $498,315.00. Following the completion of the acquisition, the chief executive officer directly owned 23,900 shares in the company, valued at approximately $498,315. The trade was a ? increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold 1,043 shares of company stock worth $21,851 in the last three months. Company insiders own 4.00% of the company’s stock.

Wall Street Analysts Forecast Growth

PRCT has been the topic of a number of recent analyst reports. Piper Sandler raised PROCEPT BioRobotics to a “strong-buy” rating in a report on Friday, October 16th. Robert W. Baird set a $20.00 price target on PROCEPT BioRobotics in a research note on Wednesday, August 5th. Truist Financial set a $21.00 price target on PROCEPT BioRobotics in a report on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Thursday, October 15th. Finally, Evercore set a $23.00 price objective on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Three analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $25.50.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation is a medical technology company focused on developing and commercializing robotic solutions for the treatment of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms. The company’s technology is designed to provide a minimally invasive alternative to conventional surgical procedures.

Its primary product is the AquaBeam Robotic System, which uses image guidance, robotic assistance and a high-velocity waterjet to remove targeted prostate tissue.